explore -WSS

explore

author：comprehensive 2025-10-02 22:26:37 - browse：9755

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Stop the failed accountable care organization experiment

WSS

Asbestos, a deadly carcinogen, banned by EPA

Update the Apgar Score to remove skin color

Inaction leaves children at risk from dangerous chemotherapy drug

TikTok, Instagram influencers need more rules for drug ads

Prior authorization reform is both possible and imperative

Printout prescription drug information shouldn’t go digital

entertainment

explore

entertainment

Apple is now the first public company to be valued at $3 trillion

Printout prescription drug information shouldn’t go digital

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Flu vaccine reformulation won't be easy, manufacturers warn

Wildfire smoke exposes gaps in outdoor worker protections

HPV vaccine, cervical cancer study delivers historic results

The high cost of giving birth even with insurance

Microsoft launches AI tool for clinical documentation through Epic

In Memoriam: Notable people who died in 2023

SCOTUS questions limit to govt efforts to fight misinformation

explore

Inaction leaves children at risk from dangerous chemotherapy drug

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Flu vaccine reformulation won't be easy, manufacturers warn

U.K. researchers warn about biases in medical devices, algorithms

HPV vaccine, cervical cancer study delivers historic results

Orchard's therapy for neuron disease in children wins FDA approval

Wikipedia

focus

focus

explore